These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
385 related items for PubMed ID: 22340106
1. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer]. Li N, Jin ZL, Liu ZJ, Wang J, Li K. Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106 [Abstract] [Full Text] [Related]
3. [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer]. Wang J, Li K, Sun T, Zhang MJ, Li WL, Yao Q, Liu W, Ding CM, He ZY, Mao WD, Wang HM, Zhang Y, Zhou XL. Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):618-22. PubMed ID: 24314222 [Abstract] [Full Text] [Related]
4. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z, Zhang Y, Zhao Y, Jiang L, Zhou J, Jin X. J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504 [Abstract] [Full Text] [Related]
5. [A randomized comparative trial of three combined regimens containing cisplatin for treatment of advanced non-small cell lung cancer]. Liu L, Wang XW, Li L, Zhang X, Zhang WD, Yu XJ. Ai Zheng; 2006 Aug; 25(8):990-4. PubMed ID: 16965680 [Abstract] [Full Text] [Related]
6. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Li X, Gu G, Soliman F, Sanders AJ, Wang X, Liu C. Chemotherapy; 2018 Aug; 63(4):214-219. PubMed ID: 30347389 [Abstract] [Full Text] [Related]
8. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K. Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819 [Abstract] [Full Text] [Related]
10. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma. Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R. Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327 [Abstract] [Full Text] [Related]
11. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer. Zhai Y, Ma H, Hui Z, Zhao L, Li D, Liang J, Wang X, Xu L, Chen B, Tang Y, Wu R, Xu Y, Pang Q, Chen M, Wang L. Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184 [Abstract] [Full Text] [Related]
12. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Socinski MA, Sandler AB, Israel VK, Gillenwater HH, Miller LL, Locker PK, Antonellini A, Elfring GL, Natale RB. Cancer; 2002 Oct 01; 95(7):1520-7. PubMed ID: 12237921 [Abstract] [Full Text] [Related]
13. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. J Clin Oncol; 2001 Jul 01; 19(13):3210-8. PubMed ID: 11432888 [Abstract] [Full Text] [Related]
14. Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study. Rozzi A, Nardoni C, Corona M, Restuccia MR, Falbo T, Lanzetta G. J Chemother; 2010 Dec 01; 22(6):419-23. PubMed ID: 21303751 [Abstract] [Full Text] [Related]
17. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016. Ikeda S, Kato T, Ogura T, Sekine A, Oda T, Masuda N, Igawa S, Katono K, Otani S, Yamada K, Saito H, Kondo T, Hosomi Y, Nakahara Y, Nishikawa M, Utumi K, Misumi Y, Yamanaka T, Sakamaki K, Okamoto H. BMC Cancer; 2018 Mar 02; 18(1):241. PubMed ID: 29499653 [Abstract] [Full Text] [Related]
18. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J. Lung Cancer; 2005 Apr 02; 48(1):129-35. PubMed ID: 15777980 [Abstract] [Full Text] [Related]
19. Vinorelbine in combination with carboplatin followed by single-agent consolidation therapy for unresectable localized or metastatic non-small-cell lung carcinomas. Alici S, Coskun U, Alkis N, Sevinc A, Dane F, Gumus M, Ozkan M, Kaya AO, Celenkoglu G, Buyukberber S, Altunbas M, Benekli M, Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev; 2009 Apr 02; 10(6):1051-5. PubMed ID: 20192582 [Abstract] [Full Text] [Related]